New Amsterdam Pharma CO N.V. NAMS
We take great care to ensure that the data presented and summarized in this overview for NewAmsterdam Pharma Co N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NAMS
Top Purchases
Top Sells
About NAMS
Insider Transactions at NAMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,218
-17.32%
|
-
|
|
Feb 19
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,218
+14.76%
|
-
|
|
Feb 18
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
90,782
-67.35%
|
-
|
|
Feb 18
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,782
+40.25%
|
-
|
|
Jan 30
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,578
-12.47%
|
-
|
|
Jan 30
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,578
+19.08%
|
-
|
|
Jan 29
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
56,863
-56.38%
|
-
|
|
Jan 29
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,863
+36.05%
|
-
|
|
Jan 28
2025
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,900
-14.98%
|
-
|
|
Jan 28
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,900
+21.98%
|
$134,100
$9.26 P/Share
|
|
Jan 28
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,385
-19.82%
|
-
|
|
Jan 28
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,385
+26.79%
|
-
|
|
Jan 27
2025
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,983
-32.78%
|
-
|
|
Jan 27
2025
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,983
+35.6%
|
$422,847
$9.26 P/Share
|
|
Jan 27
2025
|
Douglas F Kling Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
104,174
-44.68%
|
-
|
|
Jan 27
2025
|
Douglas F Kling Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
104,174
+41.28%
|
-
|
|
Jan 07
2025
|
Mark C. Mc Kenna |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
William Lewis |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
|
Jan 07
2025
|
Louis G Lange |
BUY
Grant, award, or other acquisition
|
Direct |
6,960
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
974K
Shares
From
19
Insiders
| Grant, award, or other acquisition | 346K shares |
|---|---|
| Open market or private purchase | 19.5K shares |
| Exercise of conversion of derivative security | 609K shares |
Sell / Disposition
1.78M
Shares
From
6
Insiders
| Open market or private sale | 1.77M shares |
|---|---|
| Payment of exercise price or tax liability | 11.2K shares |